Our goal
Disrupting the respiratory diagnostic tools, especially for respiratory diseases associated with ciliary dysfunction, by development and commercialisation of an innovative endoscope capable of measuring ciliary beat frequency in real-time directly within the airways.
The technologywill enable better diagnosis and treatment of currently incurable diseases related to ciliary dysfunction, such as Primary Ciliary Dyskinesia (PCD), cystic fibrosis, and certain forms of chronic obstructive pulmonary disease (COPD).
These conditions often suffer from a lack of early and accurate diagnosis, which is crucial for effective management and treatment. By providing a real-time, non-invasive diagnostic tool that measures ciliary beat frequency (CBF) directly within the airways, we open new avenues for early detection and monitoring of these diseases.
Why?
Our technology is a solution that meets demands of both patients and healthcare providers:
- Real-Time Results: Diagnosis time reduction: from days to minutes,
- Sample free: Patient fatigue highly decreased by eliminating sample collection,
- Near-perfect diagnostic accuracy: Advanced imaging technology combined with the in-situ procedure,
- Procedure cost reduction: Even by 70% because of the high procedure simplification.
Cutting-edge technology:
- Glass 3D printed imaging bundle,
- Advanced defocusing system,
- Laser speckle analysis and visualisation software.
Market
TAM – The respiratory diagnostics market – $5.6 billion
SAM – Focusing on advanced healthcare systems, estimated at $2 billion.
SOM – in the first 3 years post-commercialization $120 million annually.
CAGR: 6.6%
Solution
A conventional cilia motility analysis.
Green arrow: Death ciliated cell
Blue arrows: Live and motile ciliated cell, the tip of the blue arrows show cilia.